The prognosis of CLL patients is still based on clinicopathological finding; however, extensive research in the field during the last decade has unleashed the prospect of adding new prognostic biomarkers for CLL in the clinical routine [7], such as cytogenetic markers, mutational status of the immunoglobulin heavy chain variable region (IGHV), CD38 expression, and zeta-chain-associated protein kinase 70 kDa (ZAP70) expression in leukemic B cells [8, 9]. Here, CD38 is linked to B-cell chronic lymphocytic leukemia.